{"success":true,"data":{"pressRelease":{"id":"65693","rtpr_id":"nPnbynPsfa","ticker":"ELTX","exchange":"NASDAQ","all_tickers":["ELTX"],"title":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)","author":"PR Newswire","published_at":"2026-06-16T20:44:00.241Z","article_body":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)\n\nPR Newswire\n\nNEW YORK, June 16, 2026\n\nElicio Therapeutics reported Q1 2026 results showing a widening net loss and\nzero revenue days before its lead clinical program failed -- investors who\nbought ELTX lost 72.5% in a single session.\n\nNEW YORK, June 16, 2026 /PRNewswire/ -- Elicio Therapeutics (NASDAQ: ELTX)\ninvestors lost approximately 72.53% of their investment value today after the\nCompany disclosed that its Phase 2 AMPLIFY-7P study of ELI-002 7P failed to\nmeet the primary disease-free survival endpoint in pancreatic cancer. On June\n9, the Company reported Q1 2026 earnings showing zero revenue and a widening\nnet loss driven by R&D spending. Six days later, shares collapsed.\nShareholders who lost money on ELTX are encouraged to submit their information\nhere\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713002-1&h=727316993&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Felicio-therapeutics-inc-class-action-lawsuit-eltx%3Fprid%3D188606%26wire%3D4&a=are+encouraged+to+submit+their+information+here)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nThe Q1 2026 filing showed the Company generated no product revenue while\nreporting increased research and development expenses tied to the AMPLIFY-7P\nprogram. The Company's cash position funded operations centered on ELI-002 7P\nas its lead pipeline candidate. On June 15, the 144-patient Phase 2 trial\nmissed its pre-specified primary endpoint.\n\nDays before the trial data became public, B. Riley Securities had issued a Buy\nrating with a $27 price target on June 10-11. The stock closed at only $4.08\nafter the Phase 2 miss was disclosed on June 15.\n\nIf you purchased Elicio Therapeutics shares and suffered a loss, click here to\ndiscuss your legal rights\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713002-1&h=3913066831&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Felicio-therapeutics-inc-class-action-lawsuit-eltx%3Fprid%3D188606%26wire%3D4&a=click+here+to+discuss+your+legal+rights)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nSueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years).\nOver 70 professionals. Hundreds of millions recovered.\n\nFrequently Asked Questions About the ELTX Investigation\n\nQ: Who is eligible to participate in the ELTX investigation? A: Investors who\npurchased ELTX stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: How much did ELTX stock drop? A: Shares fell approximately 72.5% after the\nCompany disclosed that its Phase 2 AMPLIFY-7P trial of ELI-002 7P failed to\nmeet the primary disease-free survival endpoint. Investors who purchased\nshares at higher prices may be entitled to recovery.\n\nQ: Which statements are being investigated as potentially misleading? A: The\ninvestigation concerns whether Elicio Therapeutics made materially false or\nmisleading statements regarding the prospects of ELI-002 7P and the AMPLIFY-7P\nclinical program. When the Phase 2 results were disclosed, the stock price\ndeclined sharply.\n\nQ: What do ELTX investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or (888) SueWallSt. No immediate action is\nrequired to remain eligible to participate in the investigation.\n\nQ: What happens after I contact SueWallSt? A: An attorney will review your\ntrading history at no cost and provide an initial assessment of your potential\nrecovery.\n\nQ: What if I already sold my ELTX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought ELTX and sold at a loss may still participate\nin the investigation.\n\nQ: What does it cost me to participate? A: Nothing. Securities investigations\nand any resulting actions are handled on a pure contingency basis. No upfront\nfees, no retainer, no out-of-pocket costs.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx-302802175.html\n(https://www.prnewswire.com/news-releases/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx-302802175.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1_Logo.jpg?id=OA2720630\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbynPsfa","title":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)","author":"PR Newswire","ticker":"ELTX","created":"2026-06-16T20:44:00.241Z","tickers":["ELTX"],"exchange":"NASDAQ","article_body":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)\n\nPR Newswire\n\nNEW YORK, June 16, 2026\n\nElicio Therapeutics reported Q1 2026 results showing a widening net loss and\nzero revenue days before its lead clinical program failed -- investors who\nbought ELTX lost 72.5% in a single session.\n\nNEW YORK, June 16, 2026 /PRNewswire/ -- Elicio Therapeutics (NASDAQ: ELTX)\ninvestors lost approximately 72.53% of their investment value today after the\nCompany disclosed that its Phase 2 AMPLIFY-7P study of ELI-002 7P failed to\nmeet the primary disease-free survival endpoint in pancreatic cancer. On June\n9, the Company reported Q1 2026 earnings showing zero revenue and a widening\nnet loss driven by R&D spending. Six days later, shares collapsed.\nShareholders who lost money on ELTX are encouraged to submit their information\nhere\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713002-1&h=727316993&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Felicio-therapeutics-inc-class-action-lawsuit-eltx%3Fprid%3D188606%26wire%3D4&a=are+encouraged+to+submit+their+information+here)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nThe Q1 2026 filing showed the Company generated no product revenue while\nreporting increased research and development expenses tied to the AMPLIFY-7P\nprogram. The Company's cash position funded operations centered on ELI-002 7P\nas its lead pipeline candidate. On June 15, the 144-patient Phase 2 trial\nmissed its pre-specified primary endpoint.\n\nDays before the trial data became public, B. Riley Securities had issued a Buy\nrating with a $27 price target on June 10-11. The stock closed at only $4.08\nafter the Phase 2 miss was disclosed on June 15.\n\nIf you purchased Elicio Therapeutics shares and suffered a loss, click here to\ndiscuss your legal rights\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713002-1&h=3913066831&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Felicio-therapeutics-inc-class-action-lawsuit-eltx%3Fprid%3D188606%26wire%3D4&a=click+here+to+discuss+your+legal+rights)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nSueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years).\nOver 70 professionals. Hundreds of millions recovered.\n\nFrequently Asked Questions About the ELTX Investigation\n\nQ: Who is eligible to participate in the ELTX investigation? A: Investors who\npurchased ELTX stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: How much did ELTX stock drop? A: Shares fell approximately 72.5% after the\nCompany disclosed that its Phase 2 AMPLIFY-7P trial of ELI-002 7P failed to\nmeet the primary disease-free survival endpoint. Investors who purchased\nshares at higher prices may be entitled to recovery.\n\nQ: Which statements are being investigated as potentially misleading? A: The\ninvestigation concerns whether Elicio Therapeutics made materially false or\nmisleading statements regarding the prospects of ELI-002 7P and the AMPLIFY-7P\nclinical program. When the Phase 2 results were disclosed, the stock price\ndeclined sharply.\n\nQ: What do ELTX investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or (888) SueWallSt. No immediate action is\nrequired to remain eligible to participate in the investigation.\n\nQ: What happens after I contact SueWallSt? A: An attorney will review your\ntrading history at no cost and provide an initial assessment of your potential\nrecovery.\n\nQ: What if I already sold my ELTX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought ELTX and sold at a loss may still participate\nin the investigation.\n\nQ: What does it cost me to participate? A: Nothing. Securities investigations\nand any resulting actions are handled on a pure contingency basis. No upfront\nfees, no retainer, no out-of-pocket costs.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx-302802175.html\n(https://www.prnewswire.com/news-releases/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx-302802175.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1_Logo.jpg?id=OA2720630\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-16T20:44:00.284201857Z","server_sent_at_ms":1781642640284},"received_at":"2026-06-16T20:44:00.337Z","source_url":"https://www.prnewswire.com/news-releases/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx-302802175.html"},"analysis":{"id":"55111","press_release_id":"65693","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt announced an investigation into Elicio Therapeutics' officers and directors regarding potential misleading statements about its ELI-002 7P clinical program.\n\nThe solicitation follows a roughly 72.5% single-session stock decline after the company disclosed a Phase 2 trial failure in pancreatic cancer.\n\nInvestors are encouraged to contact the firm to discuss legal rights; this is a law-firm marketing notice, not an issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"Shareholders who lost money on ELTX are encouraged to submit their information here","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"},{"name":"Ed Korsinsky","role":"Attorney"}],"products":["ELI-002 7P"],"companies":[{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"Elicio Therapeutics","ticker":"ELTX","relationship":"target"},{"name":"B. Riley Securities","relationship":"analyst"}],"dollarAmounts":[{"amount":"$27","context":"prior price target by B. Riley Securities"},{"amount":"$4.08","context":"closing price after trial miss"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by SueWallSt. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff solicitation."},"tickerRelevance":{"others":[],"primary":"ELTX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt announced an investigation into Elicio Therapeutics' officers and directors regarding potential misleading statements about its ELI-002 7P clinical program.\n\nThe solicitation follows a roughly 72.5% single-session stock decline after the company disclosed a Phase 2 trial failure in pancreatic cancer.\n\nInvestors are encouraged to contact the firm to discuss legal rights; this is a law-firm marketing notice, not an issuer disclosure.","key_figures":null,"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"},{"name":"Ed Korsinsky","role":"Attorney"}],"products":["ELI-002 7P"],"companies":[{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"Elicio Therapeutics","ticker":"ELTX","relationship":"target"},{"name":"B. Riley Securities","relationship":"analyst"}],"dollarAmounts":[{"amount":"$27","context":"prior price target by B. Riley Securities"},{"amount":"$4.08","context":"closing price after trial miss"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-16T20:45:24.197Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":83845,"modelName":"george-droid-qwen-72b"}}